INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Edwards Lifesciences Corporation (NYSE: EW); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel

Core Viewpoint - A class action lawsuit has been filed against Edwards Life Sciences Corporation, alleging violations of federal securities laws related to misleading statements about its Transcatheter Aortic Valve Replacement (TAVR) platform and its financial performance during the class period from February 6, 2024, to July 24, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit represents all individuals and entities that purchased Edwards securities during the specified class period and claims that the company and certain executives made materially false and misleading statements [1][3]. - Investors have until December 13, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1]. Group 2: Company Background - Edwards Life Sciences is an international company focused on researching, developing, and providing products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions [3]. Group 3: Allegations and Financial Impact - The lawsuit alleges that the defendants concealed material adverse facts regarding the TAVR platform, emphasizing their commitment and confidence in its demand in lower-penetrated markets [3]. - On July 24, 2024, Edwards reported disappointing second-quarter financial results and reduced its revenue guidance for the TAVR platform, attributing the poor performance to increased pressure on hospital workflows from the growth of structural heart therapies [4]. - Following the announcement of these results, Edwards's stock price fell by $27.25 per share, representing a nearly 32% decline [4].